Nitroglycerin exerts a direct myocardial anti-ischemic effect even in the state of vascular nitrate tolerance. To examine the potentially diverse molecular responses in vascular and cardiac tissues, we investigated the gene expression profile of the heart and the aorta by DNA microarray in male Wistar rats that were previously made tolerant to the vascular effects of nitroglycerin. The blood pressure lowering effect of nitroglycerin (1-100 µg/kg) was markedly attenuated in rats pre-treated for 3 days with 3x100 mg/kg nitroglycerin. Nitric oxide content was significantly elevated in the heart but not in the aorta of nitrate-tolerant animals, which indicated tissuespecific differences in nitroglycerin bioconversion. Out of 7742 genes analyzed by DNA microarray, we found that while the expression of 25 genes changed significantly in the heart (increased: Tas2r119, Map6, Cd59, Kcnh2, Kcnh3, Senp6, Mcpt1, Tshb, Haus1, Vipr1, Lrn3, Lifr; decreased: Ihh, Fgfr1, Cryge, Krt9, Agrn, C4bpb, Fcer1a, Csf3, Hsd17b11, Hsd11b2, Ctnnbl1, Prpg1, Hsf1), only 14 genes were altered in the aorta (increased: Tas2r119, Ihh, Rrad, Npm1, Snai1; decreased: Tubb2b, Usp15, Sema6c, Wfdc2, Rps21, Ramp2, Galr1, Atxn1, Lhx1) in vascular nitrate tolerance. QRT-PCR analysis of genes related to oxidative/nitrative/nitrosative stress also showed differential expression pattern in the heart and aorta. This is the first pharmacogenomic analysis showing that nitroglycerin treatment leading to vascular nitrate tolerance differentially impacts gene expression in vascular and cardiac tissues, which indicates different tissue-specific downstream signaling pathways.
Introduction
Organic nitrates have been among the most widely used drugs for the treatment of ischemic heart disease, a leading cause of death, for more than a century. The major effect of nitrates has been attributed to their vasodilator function and the resulting reduction of cardiac preload and afterload. However, development of vascular tolerance due to prolonged use reduces the clinical effectiveness of nitrate therapy. The principal causes of vascular nitrate tolerance are believed to be decreased bioavailability of nitric oxide (NO) derived from nitrates, counter-regulatory neurohormone activation and oxidative/nitrative/nitrosative stress 1, 2 . Despite the potential for tolerance development, chronic nitrate use was associated with a shift away from ST-segment elevation myocardial infarction to non-ST-segment elevation acute coronary syndrome with smaller release of myocardial necrotic markers in a large scale clinical trial 3 .
Interestingly, nitrates also exert a direct myocardial anti-ischemic effect, which is independent of their hemodynamic action and is preserved even in the state of vascular nitrate tolerance 2, 4, 5 . Moreover, Hill and coworkers 6 have demonstrated in rabbit hearts that nitroglycerin treatment elicited a preconditioning-like effect comparable to ischemia-induced preconditioning, which was sustained even during development of nitrate tolerance. To explain the mechanisms of these phenomena, we have previously shown 4, 7 by spin trapping measurement of NO levels in nitratetolerant and non-tolerant hearts that in contrast to vascular tissue, the bioconversion of nitroglycerin is not blunted in the myocardium. We have also found that oxidative stress was not increased in the heart during nitrate tolerance 8 . Based on these findings, it was proposed that the vasculature and cardiac tissue may respond to nitroglycerin treatment in a different way, questioning the existence of myocardial nitrate tolerance 2 . To date, there is insufficient data regarding the potentially diverse cellular responses of vascular and cardiac tissues to organic nitrate treatments leading to the development of vascular nitrate tolerance, though the mechanism of nitrate action likely differ in these cell types 2 . Therefore, here we used DNA microarray analysis and QRT-PCR to monitor transcript levels in rat hearts and aortas with the hope of identifying critical differences in these tissues in response to nitroglycerin treatment which leads to vascular nitrate tolerance.
Methods
The study conforms to the 'Guide for the care and use of laboratory animals'
published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and was approved by local ethics committees. The animals were kept at 12-hour light/dark cycle and had free access to standard laboratory chow and drinking water.
Nitrate treatment and verification of vascular nitrate tolerance
To induce vascular nitrate tolerance (Figure 1 .), male Wistar rats (300-360 g)
were given nitroglycerin (100 mg/kg subcutaneously) or its vehicle (lactose) 3 times a day for 3 days as described in our earlier studies 5, 8, 9 . The animals were used for biochemical measurements on the fourth day ( and then connected to a small animal respirator whose frequency and volume were set at 50-55/min and 2.5 mL, respectively. The right carotid artery was isolated and a catheter (which was connected to a pressure transducer) was inserted for blood . Cardiac and aortic NO content were expressed as arbitrary units.
2.3. Isolation of the heart and aorta for RNA preparation Animals were anesthetized with diethyl ether and given 500 U/kg heparin intravenously. Hearts from control and nitrate-treated rats (n = 8 in each groups)
were then isolated and perfused in Langendorff mode with oxygenated, normothermic Krebs-Henseleit buffer for 5 min, as described in earlier works 4 .
Following isolation of the heart, the entire thoracic and abdominal aorta was dissected, placed in ice cold saline and trimmed of excess connective tissue. Then the ventricles and aortas from both experimental groups were blotted, immediately frozen, and powdered with a pestle and mortar in liquid nitrogen for RNA preparation.
RNA preparation
Total RNA was purified from each group (~25 mg tissue from each sample)
with NucleoSpin RNA purification kit (Macherey-Nagel, Dürren, Germany) according to the manufacturer's instructions. The quantities and qualities of RNA from each sample were assessed by gel electrophoresis as well as spectrophotometry (NanoDrop spectrophotometer, NanoDrop, USA). Two RNA pools were prepared from each group (n = 4, randomly selected from each group) and used in replica experiments. Total RNA was used for microarray analysis as well as for reverse transcription and subsequent quantitative PCR.
Microarray analysis
To monitor tissue-specific differences at the molecular level in cardiac and aortic tissues in response to nitroglycerin treatment that leads to vascular nitrate tolerance, we performed DNA microarray analysis. Microarray probes were generated by a modified version of a linear amplification technique described previously
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. Briefly, two g of total RNA from each pooled sample was amplified.
Three g of amplified RNA was labeled with both Cy5 and Cy3 fluorescent dyes Curves were analyzed by the RotorGene software using dynamic tube and slope correction methods, ignoring data from cycles close to baseline. Relative expression ratios were normalized to beta-actin and calculated with the Pfaffl method. The PCR primers used in this study are listed in Supplementary Material 1. A. Primers were designed by using the ArrayExpress software (Applied Biosystems). All the PCRs were performed four times in separate runs.
We also conducted additional QRT-PCR analyses of genes that are related to oxidative/nitrative/nitrosative stress and were not available on the microarray. The protocol for these analyses was identical to the above described method for the confirmatory QRT-PCR. The primers used in these analyses are listed in Supplementary Material 1. In separate experiments, additional QRT-PCR was conducted focusing on transcript levels of selected vascular signaling molecules (Supplementary Material 2.).
Statistics
Gene expression with p < 0.05 and log 2 ratio ≥ 0.90 or log 2 ratio ≤ -0.90
(1.87 fold change) were considered as significant up-or down-regulation, respectively. One-way ANOVA or unpaired t-test, as appropriate, was used to calculate the differences in other parameters, such as the hemodynamic values or tissue nitric oxide content, between groups (p < 0.05).
Results
As expected, nitrate-tolerant animals exhibited a significantly attenuated acute blood pressure response during our nitroglycerin tolerance test (for explanation see the methods section) ( Figure 2 ). However, there were no differences in body weight, heart weight, and basal ex vivo hemodynamic parameters between the nitratetolerant and the non-tolerant rats (Table 1) .
To study potential tissue-specific differences in the metabolism of nitroglycerin, cardiac and aortic NO content were measured by EPR after in vivo spin trapping from rats that were subjected to repeated nitroglycerin or vehicle injections.
Nitric oxide content was significantly elevated in the heart but not in the aorta of nitrate-tolerant animals when compared to non-tolerant controls ( Figure 3 ).
To assess tissue-specific responses to repeated nitroglycerin pretreatments at the transcript level, expression of 7742 genes were analyzed by DNA microarray and the expression of 25 genes changed significantly in the heart, while 14 genes were altered in the aorta in vascular nitrate tolerance.
The result of the analysis indicates that the expression of twelve genes increased (taste receptor type 2 member 119, microtubule-associated protein 6, CD59 molecule, potassium voltage-gated channel subfamily H member 2, potassium voltage-gated channel subfamily H member 3, SUMO1/sentrin specific peptidase 6, mast cell protease 1, thyroid stimulating hormone beta, HAUS augmin-like complex subunit 1, vasoactive intestinal peptide receptor 1, leucine rich repeat neuronal 3, leukemia inhibitory factor receptor alpha) and thirteen genes decreased (indian hedgehog, fibroblast growth factor receptor 1, crystallin gamma E, keratin 9, agrin, complement component 4 binding protein beta, Fc fragment of IgE, colony stimulating factor 3, hydroxysteroid (17-beta) dehydrogenase 11, hydroxysteroid 11-beta dehydrogenase 2, catenin beta like 1, proline-rich proteoglycan 1, heat shock transcription factor 1) in the heart (Table 2 and Table 3 ), while five increased (taste receptor type 2 member 119, indian hedgehog, ras-related associated with diabetes, nucleophosmin, snail family zinc finger 1) and nine decreased (tubulin beta 2B
class IIb, ubiquitin specific peptidase 15, semaphoring 6C, WAP four-disulfide core domain 2, ribosomal protein S21, receptor activity modifying protein 2, galanin receptor 1, ataxin 1, LIM homeobox 1) in the aorta (Table 2 and Table 4 ) satisfying both our threshold (at least ± 0.90 log 2 ratio) and statistical significance (p < 0.05) criteria. More importantly, there was an agreement regarding gene expression in case of only one gene (taste receptor type 2 member 119) in these tissues (Table 2) .
Apart from this gene, we found only one additional transcript (indian hedgehog) whose expression was altered by nitrate treatment in both tissues, but the direction of change was the opposite in the heart and the aorta; that is, gene expression decreased in the heart and increased in the aorta (Table 2 ). Selected significant cDNA microarray changes were verified with QRT-PCR in the case of ten genes in the heart and five genes in the aorta (Tables 2, 3 , and 4).
We also conducted additional QRT-PCR analysis of genes that were absent from the DNA microarray and may be important in relation to oxidative/nitrative/nitrosative stress. The outcome of this analysis confirmed the microarray results, indicating that the gene expression pattern was dissimilar in the heart and the aorta. Although the levels of two transcripts, nicotinamide adenine dinucleotide phosphate oxidase (NOX) 4 and nitric oxide synthase (NOS) 2 were elevated in both tissues, other changes were different (Table 5 ). For example, superoxide dismutase (SOD) 2 and SOD3 and matrix metalloproteinase (MMP) 2 expression were increased in the aorta, but not in the heart. Additionally, transcript levels of tissue inhibitor of MMP1 decreased in the aorta, with no change in the heart, while tissue inhibitor of MMP4 decreased in the heart and remained unaffected in the aorta.
The transcript levels of selected vascular signaling molecules were further investigated by QRT-PCR. There were no significant changes in expression of these selected genes (i.e. PDE1A, PDE2A2, AGTR1a, AGTR1b, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3) in response to chronic nitroglycerin treatment (Supplementary Material 2.).
Discussion and conclusion
In the present pharmacogenomic study, we demonstrated for the first time that the gene expression pattern in the heart and aorta remarkably differs in response to a nitroglycerin treatment that leads to the development of vascular nitrate tolerance.
In our microarray analysis study, only one gene (taste receptor type 2 member 119)
showed similar change in these tissues regarding the direction and magnitude of the alteration. Expression of only one other gene (indian hedgehog) was altered significantly but in an opposite direction in the heart and the aorta. All other genes showing significantly altered expression in the heart were unaffected in the aorta in response to a nitroglycerin treatment that leads to vascular nitrate tolerance.
Furthermore, genes with altered expression in the aorta were not influenced in the heart. These data suggest that the repeated nitroglycerin treatment induces a tissuespecific response at the transcript level. The tissue-specific differences were further confirmed in our present study by demonstrating that repeated nitroglycerin treatment resulted in an increased NO content in the heart but not in the aorta. Results of our cDNA microarray analysis clearly showed that only two genes were altered significantly both in the heart and the aorta at the same time, in our present study. Expression of taste receptor type 2 member 119 was increased in both tissues, while the expression of indian hedgehog was decreased in the heart and increased in the aorta following nitroglycerin treatment. The G protein-coupled taste receptor type 2 is primarily found on the tongue playing a role in detection of a variety of nutrient compounds. It has been shown recently that the taste receptor type 2 is also expressed by the rodent and the human heart with a predicted nutrient sensor function 16 . shown.
In our current study, we also showed several genes that were influenced exclusively in the aorta and were not altered in the heart in response to nitroglycerin . Therefore, we performed additional QRT-PCR analysis of genes that are related to oxidative and nitrative/nitrosative stress. These tests also confirmed our initial hypothesis, indicating that the gene expression pattern was dissimilar in the heart and the aorta.
Importantly, transcript levels of the predominant vascular NADPH oxidase isoform, NOX4, as well as SOD2 and SOD3 were increased in the aorta, likely reflecting an augmented superoxide production in the state of nitrate tolerance. Moreover, MMP2
was also elevated in the aorta, suggesting an increased oxidative stress, as ROI derived from either NOX activity or metabolism of nitroglycerin are likely involved in the expression of MMPs
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. In our present study, the expression of NOX4 gene also increased in the heart in response to chronic nitrate treatment. However, the . In addition, the cardiac effects of NOX4 are controversial in the literature, both beneficial and deleterious effects have been indicated 39, 40 . Furthermore, the predominant isoform in the adult heart is NOX2
, whose expression remained unchanged in our study. These results, with their recognized limitations, tend to support the conclusion that free radical generation plays a role in the vascular effects of nitrate tolerance, however, in agreement with previous findings, vascular nitrate tolerance does not seem to result in increased oxidative and nitrative/nitrosative stress in the heart.
In conclusion, this is the first pharmacogenomic analysis demonstrating that the heart and the aorta differentially respond to nitroglycerin treatment that causes vascular nitrate tolerance. Our findings may contribute to a better understanding of the Janus-faced nature of nitroglycerin, which is characterized by anti-anginal and direct cardioprotective effects, as well as development of tolerance and vascular dysfunction. We hope that our findings may help to open up novel directions in rational pharmacological design or development of drug combinations to prevent tolerance development and facilitate cardioprotective effects of NO-donor molecules.
Further research is needed to confirm our results in other models of nitrate tolerance, and to elucidate the exact role of differentially expressed genes in nitrate tolerance and nitrate-induced cardioprotection.
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